638220-39-0

Basic information

• Product Name: 6-METHYL-CHROMAN-4-YLAMINE
• Synonyms: 6-METHYL-CHROMAN-4-YLAMINE;6-methylchroman-4-amine;2H-1-Benzopyran-4-amine, 3,4-dihydro-6-methyl-;6-methyl-3,4-dihydro-2H-chromen-4-ylamine hydrochloride;3,4-Dihydro-6-methyl-2H-1-benzopyran-4-amine;6-Methyl-3,4-dihydro-2H-chroMen-4-aMine
• CAS NO: 638220-39-0
• Molecular Formula: C10H13NO
• Molecular Weight: 163.22
• Mol File: 638220-39-0.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 256℃
• Flash Point: 110℃
• Appearance: /
• Density: 1.079
• Vapor Pressure: 0.016mmHg at 25°C
• Refractive Index: 1.553
• Storage Temp.: 2-8°C
• PKA: 8.84±0.20(Predicted)
• CAS DataBase Reference: 6-METHYL-CHROMAN-4-YLAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 6-METHYL-CHROMAN-4-YLAMINE(638220-39-0)
• EPA Substance Registry System: 6-METHYL-CHROMAN-4-YLAMINE(638220-39-0)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• Hazardous Substances Data: 638220-39-0(Hazardous Substances Data)

Usage

General Description

6-Methyl-chroman-4-ylamine, also known as 4-Amino-6-methylchromane, is a chemical compound with the molecular formula C10H13NO. It is a substituted chroman amine derivative with potential antioxidant and radical scavenging properties. 6-METHYL-CHROMAN-4-YLAMINE has been studied for its potential applications in the pharmaceutical and food industries due to its ability to inhibit oxidation processes and prevent the formation of free radicals. Additionally, 6-Methyl-chroman-4-ylamine has shown promising neuroprotective and anti-inflammatory properties, making it a potential candidate for the development of new drugs targeting oxidative stress-related conditions and diseases.

InChI:InChI=1/C10H13NO/c1-7-2-3-10-8(6-7)9(11)4-5-12-10/h2-3,6,9H,4-5,11H2,1H3

Upstream product

• 39513-75-2 6-methyl-4-chromanone 
• 890839-03-9 6-methyl-chroman-4-one O-methyl-oxime 

Relevant articles and documents

Chroman and tetrahydroquinoline ureas as potent TRPV1 antagonists

Novel chroman and tetrahydroquinoline ureas were synthesized and evaluated for their activity as TRPV1 antagonists. It was found that aryl substituents on the 7- or 8-position of both bicyclic scaffolds imparted the best in vitro potency at TRPV1. The most potent chroman ureas were assessed in chronic and acute pain models, and compounds with the ability to cross the blood-brain barrier were shown to be highly efficacious. The tetrahydroquinoline ureas were found to be potent CYP3A4 inhibitors, but replacement of bulky substituents at the nitrogen atom of the tetrahydroisoquinoline moiety with small groups such as methyl can minimize the inhibition.

8-SUBSTITUTED 2-(BENZIMIDAZOLYL)PURINE DERIVATIVES FOR IMMUNOSUPPRESSION

The present invention provides novel purines useful for the prevention and treatment of autoimmune diseases, inflammatory disease, mast cell mediated disease and transplant rejection. The compounds are of the general formula I:

Chromanylurea compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor and uses thereof

Compounds that are antagonists of the VR1 receptor, having formula (I) [image] or a pharmaceutically acceptable salt, prodrug, or salt of a prodrug thereof, wherein A1, A2, A3, A4, R7, R8, R9, X, Y, Z, L, n, and m, are as defined herein, and are useful in disorders prevented or ameliorated by inhibiting the VR1 receptor.